Amy Case King joins The Marijuana Solution for episode 048 to discuss her legacy as one of the most influential and traveled cannabis advocates, and the best way to effect change at all levels of government. Amy brings a wealth of knowledge advocating for families and patients around the United States and at the UN and WHO. She is a consummate patient first advocate who we can all learn a lot from.
Below is the requested information asked for during the episode:
The request from the FDA has nothing to do with the US scheduling system in the big scheme of things – this request for public comment is an administrative action that is related to the request from the World Health Organization for the scientific review of cannabis by the expert committee. Every member state was sent this request.
This is the very first EVER full scientific review of cannabis (this will include a re-review of Cannabidiol) and the rules require that input be sought from all the member states – in the US when a request like this occurs they ask for the public comment because it is our law. It doesn’t really mean anything since their will be one person who will complete a report based on the public comments that will be forwarded to the WHO – however it will contain rules about the US scheduling system. In the end this action has nothing to do with changing policy in the USA. Just like with the last review about CBD.
When the WHO / ECDD reviewed CBD in November last year, it was what they call a “pre-review”. Their report included this statement:
“The ECDD therefore concluded that current information does not justify scheduling of cannabidiol and postponed a fuller review of cannabidiol preparations to May 2018, when the committee will undertake a comprehensive review of cannabis
and cannabis related substances.”
I have attached the link to the WHO – there you will find the questionnaire that was sent to the member states. The most important thing to understand about this international process is that this is a special session where the only substance being evaluated is cannabis. Typically this review happens in November with other substances.
The Marijuana Solution Partners: